Borders Formulary Committee. Annual report 2012/13

Transcription

1 Borders Formulary Committee Annual report 2012/13 1. Purpose Borders Formulary Committee is a sub committee of the Area Drug and Therapeutics Committee and is accountable to the Strategy Group. Its purpose is to provide the Board with the assurance that mechanisms are in place and effective across NHS Borders to manage requests to prescribe medicines. 2. NHS Borders Formulary Committee (BFC) 2.1 Composition During the financial year ending 31 March 2013 membership of NHS Borders Formulary Committee comprised: Alison Wilson (Chair) Director of Pharmacy Senior Clinical Pharmacist Medicines Management Formulary Pharmacist Lead Prescribing Support Pharmacist Senior Clinical and Development Pharmacist Dr Consultant Anaesthetist Dr Declan Hegarty GP Neidpath Practice, Peebles (finished October 2012) Dr Paul Marynicz, Coldstream Health Centre 2.2 In attendance: Susan Hogg (Minute taker) 2.3 Business Core agenda items on the Committee s agenda include: Borders Joint Formulary Updates Patient Safety Committee members present requests for drugs to be included in the formulary. The Committee noted medicines reviewed by the Scottish medicine Consortium (SMC), and guidance published by NICE and NHS Quality Improvement Scotland (QIS). 3. Outcomes Details of attendees, applications and decisions are summarised below.

2 ATTENDEES, APPLICATIONS & DECISIONS BFC MEETINGS 2012/13 BFC MEETING OF 18 TH APRIL 2012 Alison Wilson Paliperidone *Please be aware that CAT F for 3 Hosp: 3 Palmitate I cannot identify the patients (Prolonged release hospital patients that Prac:4 suspension for then come under Total: 7* injection) Primary Care for their medication. Nortriptyline (Allegron) Shona Smith CAT A Hosp: 3 Prac: 46 Pregabalin (Lyrica) Lidocaine (Versatis patches) Shona Smith Shona Smith CAT A for up to 120 patients per year To go to ADTC approved for up to 60 patients per year. Total: 49* Hosp: 143 Prac: 533 Total: 676* Hosp: 143 Prac: 252 Total: 395* Romiplostim Dr A Okhandiar CAT B Hosp: 0 Etanercept Dr N N Soe CAT B Hosp: 0 Nutricia preop Dr H Matthews CAT B Hosp: 0 200ml carton (locum Consultant) Dexamphetamine Dr M Foreman CAT B Hosp: 0 Complex Ustekinumab (Stelara) Dr S Laube CAT B Hosp: 1 Orlistat Joeleen McKeen Approved for patients with a BMI of >35. For GP use with input from dietetic PleureX (Peritoneal Catheter draining system) Dr Annabel Howell service. To be discussed with our Procurement lead. Hosp: 2 Prac: 134 Total: 136* Hosp: 0 Colecalciferol Dr A Pearson CAT A Hosp: 9 Prac: 52 Total: 61* Capsaicin Dr C Smith CAT B for up to 5 patients. Clobetasol Propionate Shampoo (Etrivex) Fluorouracil 0.5% Salicylic Acid 10% Cutaneous Sol (Actikerall) Hosp: 6 Prac: 38 Total: 44* Dr S Laube CAT A Hosp: 0 Prac: 4 Total: 4 Dr S Laube CAT A Hosp: 0 Prac: 9 Total:

3 BFC MEETING OF 13 TH JUNE 2012 Alison Wilson Dr P Marynicz Duloxetine Shona Smith CAT A Hosp: 31 Prac: 161 Total: 192* Urea 5% & Ceramide 0.1% (Balneum) Dr S Laube Hosp: 7 Prac: 15 White soft paraffin 13.2%, light liquid paraffin 10.5% (Cetraben emollient Cream) Urea 5% Lauromacrogols 3% (Balneum Plus) Cream Glycerol 10% light liquid paraffin 10% White soft paraffin 5% (QV Cream) Intensive ointment light liquid paraffin 50.5 % white soft paraffin 20% (QV Intensive Ointment) Lotion white soft paraffin 5% (QV Lotion) Enzyme alginogel with glucose oxidase and lactoperoxidase (Flaminal Forte) (Flaminal Hydro) Natalizumab (Tysabri) Carboxymaltose Ferinject (Ferric Carboxymaltose) Check to see if EMISS guidance in formulary and bring to ADTC meeting. Total: 22* Dr S Laube As above. Hosp: 0 Dr S Laube The paper showed Urea 10% but Balneum Plus is 5%. Dr S Laube/ Helen McKendrick Prac: 114 Total: 114 As above. Bal Plus Hosp: 3 To go to wound group and bring back to the next ADTC meeting. Bal Plus Prac: 115 Total: 118* QV Crm Hosp: 0 QV Crm Prac: 3 Total: 3 Intensive Hosp: 0 Intensive Prac: 1 Total: 1 Lot Hosp: 0 Lot Prac: 2 Total: 2 Forte Hosp: 1 Forte Prac: 11 Total: 12* Hydro Hosp: 2 Hydro Prac: 9 Total: 11* Dr D Simpson CAT B Hosp: 0 Dr C Evans CAT B Preference to stock one drug in the dept. ask applicant if happy to use first drug. Finasteride Dr McKay Approved and Consultant to prescribe for a trial period of 6 months then prescribed by GP Hosp: 6 Hosp: 132 Prac: 910 Total: 1042*

4 BFC MEETING OF 8 TH AUGUST 2012 Alison Wilson Octenisan Dr E James CAT F Hosp: 0 Declan Hegarty Total: 0 Chlorthalidone 50mg To be brought (Chlortalidone back to next Hygroton) BFC meeting. Indapamide 2.5mg Indapamide 1.5ng MR Chlor Hosp: 1 Chlor Prac: 8 Total: 9* Indap 2.5 Hosp: 3 Indap 2.5 Prac: 147 Total: 152* Indap 1.5 Hosp: 9 Indap 1.5 Prac: 14 Total: 23* BFC MEETING OF 17 TH OCTOBER 2012 Alison Wilson Fingolimod Dr D Simpson CAT B Hosp: 0 Denosumab (Prolia) Dr A Gordon Hosp: 219 Prac: 8 Previously approved for 3 patients. Ask applicant if they can forecast number of patients who would require this for the rest of the year. Total: 227* BFC MEETING OF 12 TH DECEMBER 2012 Alison Wilson Ranibizumab Dr D Simpson CAT B Hosp: 92 (2.3mg/0.23mL) Aclidinium Dr J Faccenda Dr J Faccenda CAT A Hosp: 0 Prac: 1 Total: 1 Fluticasone proprionate and formoterol fumarate metered dose inhaler (Flutiform) Immunoglobulin 10mg vials (Gamunex, Kiovig or Octagam) Dr P Eunson >50 patients. Circulate For noting only. Approved for 3 month trial contact RSCH for further advice. Hosp: 1 Prac: 8 Total: 9* Hosp: 12

5 BFC MEETING OF 13 TH FEBRUARY 2013 Alison Wilson Paul Marynicz Desogestrel (Cerelle) Dr A Wylie No advice from SMC recommended that the branded Hosp: 14 name of Cerelle is prescribed. Total: 14 Denosumab Dr A Pearson CAT A for 5 Hosp: 219 (Prolia) patients. Prac: 8 Invited to attend Total: 227* Judith Smith Naltrexone Dr G Cook Not approved to Hosp: 1 Val Gibson try other alternatives as not a recognised treatment for Total: 1 this condition. Pravastatin Not approved Hosp: 22 Prac: 210 Total: 232* Mistletoe therapy Dr R Smith Not approved. Hosp: 0 Total: 0